

## Emmaus Medical to Present at 6<sup>th</sup> Annual OneMedForum

TORRANCE, Calif., December 19, 2012 – [Emmaus Medical, Inc.](#), a specialty pharmaceutical and regenerative medicine company, today announced that Peter Ludlum, the company's executive vice president and CFO, will give an overview of the company's Phase 3 sickle cell disease trial and discuss recent developments with its regenerative medicine research at the 6th Annual OneMedForum on January 8, 2013 at 9:50 a.m. P.T. at the Sir Francis Drake Hotel in San Francisco. Additionally, Yutaka Niihara, M.D., MPH, president and CEO, and Willis Lee, chief operating officer, will join Ludlum for one-on-one meetings throughout the day.

### **About Emmaus Medical, Inc.**

Founded in 2000, Emmaus Medical, Inc. is a specialty pharmaceutical company, and subsidiary of Emmaus Life Sciences, Inc., dedicated to the discovery, development and commercialization of innovative and cost-effective treatments and therapies for rare diseases. The company is completing its Phase 3 clinical trial for a treatment for sickle cell disease and has entered into a collaborative agreement for the research, development and commercialization of regenerative medicine products. For more information, please visit [www.emmausmedical.com](http://www.emmausmedical.com) and [www.nutrestore.com](http://www.nutrestore.com).

Contacts:

#### **Media:**

IQ PR, Inc.  
Lori Teranishi  
415-981-1964  
[lteranishi@iqprinc.com](mailto:lteranishi@iqprinc.com)

#### **Investors:**

PondelWilkinson  
Matt Sheldon  
310-279-5980  
[msheldon@pondel.com](mailto:msheldon@pondel.com)